You are here

Article Text

Article menu
Download PDFPDF
Case Reports: Reminder of important clinical lesson
Post-COVID mRNA vaccine myocarditis in children: report of two cases

Abstract

The SARS-COV-2 pandemic led to the development of several vaccinations to contain the disease. The Pfizer-BioNTech COVID-19 (BNT162b2) vaccine was recommended on May 2021 for use in children above 12 years and older. The vaccine is safe, well tolerated and highly effective. Initial reports showed no serious adverse events; however, cases of myocarditis in young healthy male adolescents have been reported. We report two cases of myocarditis/perimyocarditis who presented with short history of chest pain following administration of the second dose of the MRN COVID-19 vaccine.

  • Cardiovascular system
  • Paediatrics (drugs and medicines)
  • Vaccination/immunisation
  • COVID-19

http://dx.doi.org/10.1136/bcr-2022-253383

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.